Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib pharmacokinetic and dose-finding study in EGFR-mutated NSCLC with renal impairment or low body weight
jRCTs031180232Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Recommended dose. Started Mar 2019; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031180232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180232.